SriZen Pharma Private Limited is a research-oriented Contract Development & Manufacturing Organization (CDMO), incorporated in 2026, specializing in niche generic and specialty pharmaceutical product development. Operating from our USFDA-registered facility in Hyderabad, we develop niche generic and specialty pharmaceutical products — including injectables, ophthalmics, oral solids, films and semi-solids and complex drug-device combinations — helping partners reach global markets with high-quality products delivered on time and at the right cost. We support every stage, from product concept to regulatory filing.
From QbD-based development to tech transfer for immediate and modified release dosage forms.
Advanced stability studies and method validation under global ICH and USFDA expectations.
Scalable manufacturing solutions for oncological and non-oncological parenteral products.
Managing Director
Over 14 years of expertise in the pharmaceuticals and biopharmaceuticals
Executive Director
Ms Kotari Sindhusha, with over 5 years of experience in business operations, throughout his tenure, he has demonstrated keen insights and expertise in crucial functional areas including business development, project management, general administration, and commercial activities. Currently, he manages Sirzen pharma day-to-day operations and plays a key role in the company's overseas exports of services and products.
Founder Director
Mr Rakesh kasula, the founder of SriZen Pharma Pvt. Ltd. is strategic business development in the pharmaceutical and biopharmaceutical thrives on steering product lifecycle management and manufacturing operations to commercial success. The focus on developing channels and managing customer relationships has been pivotal for our growth trajectory in the dynamic markets of the Vietnam, US, Europe, and China.
We provide fully integrated solutions for the end-to-end development of innovative dosage forms. Leveraging Quality by Design (QbD) principles, our multidisciplined team ensures that every formulation is commercially viable and stable.
Our USFDA-registered facility is equipped with state-of-the-art chromatographic and spectroscopic instruments. We provide data-driven certainty through high-precision impurity profiling and ICH-compliant stability management.
SriZen acts as a bridge between development and comm ercial manufacturing. We specialize in high-entry-barrier products, including complex oncology and parenteral formulations in a regulatory-safe environment.
Our technical team is ready to discuss your specific pharmaceutical R&D and manufacturing requirements.
SriZen Pharma manufacturing partnerships span domestic pharma hubs and international regulated markets.
Discuss your manufacturing requirements with our CDMO leadership team.
At SriZen Pharma, we believe that a great scientific partner is also a great business partner. Our engagement models are designed to align our success with yours — combining scientific capability with flexible commercial structures to deliver outcomes that work for both parties.formulations in a regulatory-safe environment.
SriZen Pharma operates across four primary business models, each designed to match the specific stage, risk profile, and commercial objectives of our partner.
From straightforward fee-for-service development engagements to long-term co-development and out-licensing relationships, we structure our partnerships to create genuine, sustainable value.
Our one-stop-shop approach means that regardless of the engagement model, partners benefit from the same integrated team of formulation scientists, analytical experts, regulatory professionals, and project managers — working together to move products forward efficiently and compliantly.
SriZen Pharma operates across multiple business engagement models tailored to pharmaceutical innovators and regulated market partners.
From straightforward fee-for-service development to strategic co-development and out-licensing opportunities, our integrated approach ensures agility, transparency, and long-term commercial value.
SriZen Pharma supports diverse collaboration structures designed to align with your strategic, commercial, and development objectives.
Fee For Service Scientific development engagements with defined project scope and rapid execution timelines.
Licensing-ready assets and dossiers for regulated and semi-regulated international markets.
Strategic collaborative programs where innovation, risk, and investment are jointly shared.
Integrated manufacturing partnerships leveraging India and global GMP-compliant networks.
© Copyright 2026. All Rights Reserved.